News Filter by: Industry Team Airport & AviationAutomotiveEnergyFood & Beverage Health CareHospitality & LeisureInsurance & ReinsuranceLife Sciences ManufacturingSportsTechnology Practice Area Business Law All Business LawEmployee Benefits & Executive CompensationEnvironmental RegulationEstates & TrustsFinance & Financial Institutions Private Equity & Venture CapitalReal EstateSecurities, Commodities & Exchange RegulationTaxationTransactional & Securities Government & Public Policy All Government & Public PolicyEPA RegulatoryExport Controls & National SecurityFDA RegulatoryFederal & State Energy RegulatoryFreight & Commuter Rail Government ProcurementImmigration, Nationality & Consular LawPolitical LawPublic PolicyStrategic Communications Intellectual Property All Intellectual PropertyBusiness Method & Software PatentsChemical, Biotechnology & PharmaceuticalCybersecurityElectronicsGreen Energy Technologies IP Due DiligenceIP LitigationMechanical & Electromechanical TechnologiesPatent Office TrialsTechnology Transactions & OutsourcingTrademark, Copyright & Advertising Counseling International All InternationalChinaEurope JapanLatin America Litigation All LitigationAntitrustAppellateBankruptcy & Business ReorganizationsBusiness Litigation & Dispute ResolutionConstructionConsumer Law, Finance & Class Action Distribution & FranchiseGovernment Enforcement, Compliance & White Collar DefenseInsurance & Reinsurance LitigationLabor & EmploymentPrivacy, Security & Information ManagementSecurities Enforcement & LitigationTrade Secret Noncompete Litigation Office BostonChicagoDetroitJacksonvilleLos AngelesMadison MiamiMilwaukeeNew YorkOrlandoSacramentoSan Diego San FranciscoSilicon ValleyTallahasseeTampaTokyoWashington, D.C. Topic Big DataCuba Foreign Corrupt Practices Act (FCPA)Health Care Reform Telemedicine In the News Press Releases Media Contact Jill Chanen Public Relations Manager jchanen foley.com 312.832.4745 12next 15 August 2017 Foley Attorneys Recognized in The Best Lawyers in America 2018 List –Best Lawyers Foley announced today that 25 attorneys earned Best Lawyers® 2018 “Lawyer of the Year” recognition in their respective practice areas, receiving the top nod from Best Lawyers. 25 July 2017 Rosen Comments on Implications of Delay on Passing FDARA –Pink Sheet Partner David Rosen told Pink Sheet in an article, “FDA Gives Congress Reprieve on Deadline for Passing User Fee Bill,” that most Senators are still pushing to get the FDA Reauthorization Act done prior to October 1, 2017. 14 July 2017 Rosen Comments on FDA User Fee Legislation –Modern Healthcare In Modern Healthcare’s article, “House Passes Bipartisan FDA User Fee Bill,” Partner David Rosen discussed the impact of new legislation passed in the House of Representatives that reauthorizes the FDA’s ability to collect user fees from drug and device makers. 09 May 2017 Rosen Quoted on New Safety Threats with Approved Drugs –Modern Healthcare Partner David Rosen was quoted in a Modern Healthcare article, “New Safety Threats Identified in One-Third of Drugs Post-Approval.” 24 October 2016 Rosen Quoted on Obstacles to Generic EpiPen –Reuter’s Westlaw Partner David Rosen participated in a question and answer session with Reuter’s Westlaw, “Q&A: Foley & Lardner’s David Rosen on Obstacles to Generic EpiPen,” on October 24, 2106. 22 September 2016 Rosen Quoted on FDA Requirements for Drug Shelf Life –Modern Healthcare Partner David Rosen was quoted in a Modern Healthcare article, “Extending EpiPen Shelf Life Could be a Relief for Patients, Costly for Mylan,” on September 22, 2016. 25 August 2015 Beaver Quoted on FDA Warning –Inc. Partner Nathan Beaver was quoted in an Inc. article, “Hampton Creek CEO: No Plans to Change Name of ‘Just Mayo’ Despite FDA Warning,” on August 25, 2015. 16 March 2015 Beaver Quoted on Food Safety System –Fortune Partner Nate Beaver was quoted in a Fortune article, “Could This Plan Finally Stop Food Contamination?” on March 16, 2015. The article discussed the Obama Administration’s... 03 July 2014 Rosen Quoted on Research Firm Asking FDA to Clear Path for Generic Fosamax –Law360 Partner David Rosen was quoted in a Law360 article published on July 3, 2014, titled “Research Firm Asks FDA to Clear Path for Generic Fosamax.” The article discussed... 31 January 2014 Rosen Quoted on FDA Warning Letters Issued to Drug Compounders –Inside Health Policy Partner David Rosen was quoted in an Inside Health Policy article on January 31, 2014 titled, “First DQSA Warning Letters Target Compounders Without Prescriptions.”... 12next Search News Filters applied: Search phrase entered: Sort results by: Most Recent Most Viewed Most Shared
15 August 2017 Foley Attorneys Recognized in The Best Lawyers in America 2018 List –Best Lawyers Foley announced today that 25 attorneys earned Best Lawyers® 2018 “Lawyer of the Year” recognition in their respective practice areas, receiving the top nod from Best Lawyers.
25 July 2017 Rosen Comments on Implications of Delay on Passing FDARA –Pink Sheet Partner David Rosen told Pink Sheet in an article, “FDA Gives Congress Reprieve on Deadline for Passing User Fee Bill,” that most Senators are still pushing to get the FDA Reauthorization Act done prior to October 1, 2017.
14 July 2017 Rosen Comments on FDA User Fee Legislation –Modern Healthcare In Modern Healthcare’s article, “House Passes Bipartisan FDA User Fee Bill,” Partner David Rosen discussed the impact of new legislation passed in the House of Representatives that reauthorizes the FDA’s ability to collect user fees from drug and device makers.
09 May 2017 Rosen Quoted on New Safety Threats with Approved Drugs –Modern Healthcare Partner David Rosen was quoted in a Modern Healthcare article, “New Safety Threats Identified in One-Third of Drugs Post-Approval.”
24 October 2016 Rosen Quoted on Obstacles to Generic EpiPen –Reuter’s Westlaw Partner David Rosen participated in a question and answer session with Reuter’s Westlaw, “Q&A: Foley & Lardner’s David Rosen on Obstacles to Generic EpiPen,” on October 24, 2106.
22 September 2016 Rosen Quoted on FDA Requirements for Drug Shelf Life –Modern Healthcare Partner David Rosen was quoted in a Modern Healthcare article, “Extending EpiPen Shelf Life Could be a Relief for Patients, Costly for Mylan,” on September 22, 2016.
25 August 2015 Beaver Quoted on FDA Warning –Inc. Partner Nathan Beaver was quoted in an Inc. article, “Hampton Creek CEO: No Plans to Change Name of ‘Just Mayo’ Despite FDA Warning,” on August 25, 2015.
16 March 2015 Beaver Quoted on Food Safety System –Fortune Partner Nate Beaver was quoted in a Fortune article, “Could This Plan Finally Stop Food Contamination?” on March 16, 2015. The article discussed the Obama Administration’s...
03 July 2014 Rosen Quoted on Research Firm Asking FDA to Clear Path for Generic Fosamax –Law360 Partner David Rosen was quoted in a Law360 article published on July 3, 2014, titled “Research Firm Asks FDA to Clear Path for Generic Fosamax.” The article discussed...
31 January 2014 Rosen Quoted on FDA Warning Letters Issued to Drug Compounders –Inside Health Policy Partner David Rosen was quoted in an Inside Health Policy article on January 31, 2014 titled, “First DQSA Warning Letters Target Compounders Without Prescriptions.”...